The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction

Korean Circulation Journal

Volumn 40, Issue 3, 2010, Pages 119-124

  Cho, Jung Hyun ^a   Jeong, Young Hoon ^a   Ahn, Yeon Jeong ^a   Kang, Min Kyung ^a   Koh, Jin Sin ^a   Kim, In Suk ^a   Park, Yongwhi ^a   Hwang, Seok Jae ^a   Kwak, Choong Hwan ^a   Hwang, Jin Yong ^a  

^a Gyeongsang National University   (South Korea)

Author keywords

Acute myocardial infarction; Post clopidogrel platelet reactivity; Smoking

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL;

ACUTE HEART INFARCTION; ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY STENT; EMERGENCY WARD; FEMALE; HUMAN; LIGHT TRANSMITTANCE AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; SMOKING; THROMBOCYTE AGGREGATION;

EID: 77950983043     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.3.119     Document Type: Article

References (29)

1. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-207
2. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-1563
3. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260
4. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or baremetal stents. J Am Coll Cardiol 2008;51:1925-1934
5. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-37
6. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999;36:425-438
7. Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531-533
8. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317
9. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175
10. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with high post-treatment platelet reactivity. J Am Coll Cardiol 2009;53:1101-1109
11. Jeong YH, Kim IS, Choi BR, Kwak CH, Hwang JY. The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay. Eur Heart J 2008; 29:2186-2187
12. Iba MM, Fung J, Pak YW, et al. Dose-dependent up-regulation of rat pulmonary, renal, and hepatic cytochrome P-450 (CYP) 1A expression by nicotine feeding. Drug Metab Dispos 1999;27: 977-982
13. Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999;9: 131-144
14. Berger JS, Bhatt DL, Steinhubl SR, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009;120:2337-2344
15. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009;53:1273-1278
16. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006;368:647-658
17. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731-1737
18. Cho JY, Jeong MH, Ahn YK, et al. Predictive factors of major adverse cardiac events and clinical outcomes of acute myocardial infarction in young Korean patients. Korean Circ J 2008; 38:161-169
19. Lim SY, Jeong MH, Yang BR, et al. Long-term clinical outcomes after primary percutaneous coronary intervention in patients with acute myocardial infarction older than 75 years. Korean Circ J 2005;35:613-619
20. Cho JY, Jeong MH, Choi OJ, et al. Predictive factors after percutaneous coronary intervention in young patients with acute myocardial infarction. Korean Circ J 2007;37:373-379
21. Fusegawa Y, Goto S, Handa S, Kawada T, Ando Y. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb Res 1999;93:271-278
22. Ichiki K, Ikeda H, Haramaki N, Ueno T, Imaizumi T. Long-term smoking impairs platelet-derived nitric oxide release. Circulation 1996;94:3109-3114
23. Sawada M, Kishi Y, Numano F, Isobe M. Smokers lack morning increase in platelet sensitivity to nitric oxide. J Cardiovasc Pharmacol 2002;40:571-576
24. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1058
25. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354-362
26. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med 2009;360:411-413
27. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. Nat Clin Prac Cardiovasc Med 2006;3:387-395
28. Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008;6:54-61.
29. Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008;9:1251-1259